Cyclooxygenase-2 (COX-2) has been implicated in a variety of human malignancies and, accordingly, COX-2 selective inhibitors are being investigated as important chemopreventive and therapeutic agents. How COX-2 overexpression results in tumorigenesis and how COX-2 selective agents mediate their chemopreventive effects are issues that remain poorly understood. Here we report that the tumor suppressor p53 upregulates COX-2 expression and that COX-2 can in turn inhibit p53-dependent transcription. Additionally, a COX-2-selective inhibitor potentiates p53-induced apoptosis, which also supports the notion that COX-2 activity appears to interfere with p53 function. Expression of exogenous COX-2 in p53 wildtype cells does not affect the cytoplasmic or nuclear levels of p53, suggesting that COX-2 may not affect p53 turnover or subcellular localization. We further demonstrate that endogenous COX-2 interacts with p53 and that COX-2 and p53 interactions are a physiologically relevant event. Thus, p53 upregulates COX-2 and COX-2 in turn appears to negatively affect p53 activity via mechanisms that could involve physical interactions between COX-2 and p53. Based on our results, we propose that p53-dependent upregulation and activation of COX-2 appear to be yet another novel mechanism by which p53 could abate its own growth-inhibitory and apoptotic effects.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for their analgesic, antipyretic, and antiinflammatory effects. A number of studies have also suggested that the use of NSAIDs may prove beneficial in the prevention of various types of cancers (reviewed in Williams et al., 1999; Thun et al., 2002) . NSAIDs mediate their effects primarily by inhibiting two cyclooxygenase isoenzymes, COX-1 and COX-2, both of which catalyse the formation of prostaglandins from arachidonic acid (Williams et al., 1999; Thun et al., 2002) . Unlike COX-1, which is constitutively expressed, COX-2 expression is induced by proinflammatory cytokines, tumor promoters, growth factors, and viral transformation (Williams et al., 1999; Thun et al., 2002) . COX-2 is overexpressed in various human malignancies and studies with animal models strongly support the role of COX-2 in tumorigenesis (Williams et al., 1999; Thun et al., 2002) . Accordingly, COX-2 selective inhibitors that do not exhibit the gastrointestinal side effects of traditional NSAIDs have been synthesized and are currently in National Cancer Institute-sponsored clinical trials to investigate their efficacy in the prevention of colon, skin, and bladder cancers (Williams et al., 1999; Smigel, 2000; Thun et al., 2002) .
How COX-2 overexpression results in tumorigenesis and how COX-2 selective agents mediate chemopreventive effects are issues that remain poorly understood. Thus, a better understanding of the molecular mechanisms that control COX-2 expression is needed. In this regard, recent studies have reported that the tumor suppressor p53 regulates COX-2 expression, although one shows that p53 upregulates COX-2 (Han et al., 2002) , while others show that p53 negatively effects COX-2 expression (Subbaramaiah et al., 1999; Gallo et al., 2003) . The tumor suppressor, p53, has been implicated in a variety of cellular processes but its role in growth arrest and apoptosis remains undisputed (Giaccia and Kastan, 1998; Sheikh and Fornace, 2000; Hofseth et al., 2004) . p53 functions as a transcription factor to modulate the expression of downstream target genes involved in the antiproliferative response (Giaccia and Kastan, 1998; Sheikh and Fornace, 2000; Hofseth et al., 2004) . p53 is the most frequently mutated gene in human cancer, with most mutations greatly reducing its DNA-binding and transcriptional activation potential (Giaccia and Kastan, 1998; Sheikh and Fornace, 2000; Hofseth et al., 2004) . Thus, p53 and COX-2 are two important molecules that are intimately linked to tumorigenesis. Further studies are needed to determine whether indeed p53 modulates COX-2 expression and, if it does, whether COX-2 expression is positively or negatively regulated. Reciprocally, whether COX-2 regulates p53 expression or function is an unexplored issue and therefore also warrants further investigation. A detailed study addressing the molecular basis for p53 and COX-2 interactions is likely to not only improve our understanding of cancer development and progression but also facilitate the development of more potent and less toxic COX-2 inhibitors. We therefore undertook this study to explore the aforementioned issues.
To investigate the effect of p53 on COX-2 expression, we utilized DLD1 human colon cancer cells harboring a 'bidirectional tet-off expression vector' system controlling the inducible expression of exogenous wild-type p53 (Yu et al., 1999) . In these cells, the expression of p53 is repressed when they are grown in the presence of tetracycline or doxycycline, but induced when the antibiotic is removed from the growth medium. Figure 1a shows that induction of p53 expression in these cells was associated with a marked increase in the endogenous COX-2 mRNA levels within 4 h. We also performed Western blot analyses to confirm that the increases in COX-2 mRNA levels were coupled with concomitant increases in COX-2 protein levels. As shown in Figure 1b , COX-2 protein levels were also increased in p53-induced cells. To confirm the functionality of p53, we also analysed the expression of p21
Waf1
, a well-established downstream target of p53. As is shown in Figure 1b , p21
Waf1 levels were also increased in a manner similar to that noted for COX-2. Our results thus demonstrate that p53 does indeed upregulate COX-2 expression.
COX-2 has been implicated in positive regulation of growth and tumorigenesis, while the tumor suppressor p53 is a negative regulator of these processes. Consequently, p53-dependent upregulation of COX-2 would appear rather incongruous. p53 has, however, been shown to directly upregulate the expression of genes whose products positively effect cell growth. For example, the p53 downstream target MDM2 has been associated with positive effects on cell growth (AlarconVargas and Ronai, 2002) and an autoregulatory feedback loop exists between MDM2 and p53 such that MDM2 inactivates p53 by facilitating its proteasomal degradation (Alarcon-Vargas and Ronai, 2002) . It would therefore be possible that p53-dependent upregulation and activation of COX-2 could be a compensatory response where p53, by activating COX-2, would abate its own negative growth-regulatory effects. Since p53 functions as a transcription factor to regulate the expression of its target genes, we reasoned that p53-mediated COX-2 upregulation could serve to abate the negative effects of p53 by abrogating p53 transcriptional activity.
To examine the effect of COX-2 on the transcriptional function of p53, we utilized the PG13-luciferase reporter construct that harbors 13 copies of the wild-type p53-binding site (Majumder et al., 2001; Wang and El-Deiry, 2003) . PC-3 human prostate cancer cells that are null for p53 were transiently transfected with the PG13 reporter vector along with p53 and COX-2 expression constructs, and luciferase activity was determined. As shown in Figure 2a , expression of increasing amounts of COX-2 in combination with the constant amounts of p53 resulted in a 'dose-dependent' decrease in the relative luciferase activity. Next, we investigated whether COX-2 would similarly interfere with p53 regulation of a native promoter. PUMA is one of the key downstream targets of p53 (Nakano and Vousden, 2001; Yu et al., 2001) . p53 upregulates PUMA transcription by directly binding to p53 response elements present within the PUMA gene promoter (Han et al., 2001; Yu et al., 2001) . We therefore tested the effects of COX-2 on the p53-mediated regulation of PUMA gene promoter activity. As shown in Figure 2b , COX-2 also interferes with p53 induction of the PUMA promoter. These effects were specific for PG13 construct and PUMA promoter, since both COX-2 and p53 either alone or in combination did not affect GADD153 gene promoter activity (data not shown). Taken together, these results demonstrate that COX-2 does indeed interfere with the transcriptional activation potential of p53. or absence (p53-induced) of doxycycline (Dox) for indicated periods of time, harvested and then subjected to Northern analysis as described previously (Luo et al., 2003) . The blot was sequentially probed with 32 P-labeled COX-2 and GAPDH cDNA probes; ethidium bromide staining of the 28S ribosomal RNA is also shown to illustrate comparable loading and RNA integrity. (b) A representative Western blot showing the effect of inducible wildtype p53 on endogenous COX-2 protein levels in p53-inducible DLD1 cells. Western blotting was performed as described previously (Sheikh et al., 1998; Huang et al., 2001; Luo et al., 2003) using goat anti-COX-2 (Santa Cruz Biotechnologies Inc., Santa Cruz, CA, USA), mouse anti-p53 (Ab-2, Oncogene Research, San Diego, CA, USA), and mouse anti-p21 (Transduction Laboratory, Lexington, KY, USA) antibodies. The same blot was then probed for b-actin (Sigma Chemicals, St Louis, MO, USA) to show equal protein loading Next, we sought to investigate the mechanistic basis of how COX-2 interferes with the transcriptional activation function of p53. It is well established that p53-mediated MDM2 expression results in decreases in p53 protein levels by targeted proteasomal degradation (Alarcon-Vargas and Ronai, 2002) . We therefore wished to elucidate whether COX-2 expression also resulted in decreased p53 protein levels, thereby leading to abatement of p53 transcriptional activity. Towards that end, we transiently overexpressed, at very high efficiency, exogenous COX-2 in MCF-7 and HCT-116 human cancer cells lines, which harbor endogenous wild-type p53. The results shown in Figure 3a and b indicate that COX-2 overexpression in either cell line did not affect endogenous p53 protein levels. These results suggest that, unlike p53 expression, which promotes COX-2 upregulation, COX-2 overexpression does not appear to affect endogenous p53 protein levels.
As the transcription factor function of p53 requires its nuclear localization, we next investigated whether COX-2 abrogated p53 function by altering its subcellular distribution. To do this, we overexpressed COX-2 at high efficiency in HCT-116 cells, and separated nuclear and cytosolic fractions. As illustrated in Figure 3c , COX-2 had no effect on the localization of endogenous wild-type p53 in these cells, and therefore COX-2 most likely does not affect p53 function by altering its nuclear localization. Nuclear and cytosolic fraction purity is demonstrated by Western analysis for lamin B, which is a nuclear envelope protein, and b-actin, which resides in the cytoplasm (Figure 3c ). It is generally believed that COX-2 predominantly resides in the endoplasmic reticulum (ER) as well as the nuclear envelope (Spencer et al., 1998; Trifan et al., 1999; Liou et al., 2001; Grewal et al., 2003) . Our results indicate that a significant fraction of COX-2 resides in the nuclear fraction, a finding which is consistent with previous reports that show both strong perinuclear staining of COX-2 (Trifan et al., 1999) or preferential localization of COX-2 to the nuclear envelope (Morita , 1995) . Since the ER membrane is also contiguous with the nuclear membrane, it remains possible that our nuclear fractions also contain part of the ER membrane.
p53 function is tightly regulated and involves interactions with several other cellular proteins. Interactions between MDM2 and p53 are well established and, more recently, Parc has been shown to interfere with p53's function by sequestering p53 in the cytosol, thus preventing its translocation to the nucleus (AlarconVargas and Ronai, 2002; Nikolaev et al., 2003) . It was therefore possible that COX-2 might physically interact with p53 to interfere with its transcriptional activity. The stress-induced regulation of COX-2 and p53 is a physiological cellular response, as both proteins are typically present in low levels under unstressed conditions. We therefore wished to elucidate whether endogenous COX-2 and p53 would exhibit interactions particularly in response to cellular stress. It is known that induction of p53 occurs following treatment with DNA damage-inducing agents (Hofseth et al., 2004) , whereas COX-2 levels are induced by proinflammatory stimuli such as TNF-a (Jones et al., 1993) . Additionally, evidence suggests that COX-2 expression is also enhanced in response to DNA damage (Han et al., 2002) . To investigate whether interactions between endogenous p53 and COX-2 proteins occur, we selected A549 lung cancer cells that harbor endogenous wildtype p53 as well as functional COX-2. First we tested the effect of the DNA damaging agent adriamycin, and the proinflammatory cytokine TNF-a, on p53 and COX-2 levels in these cells. As shown in Figure 4a , treatment with adriamycin and TNF-a upregulated endogenous p53 and COX-2 levels, respectively. Additionally, adriamycin also upregulated COX-2 levels, albeit its effect was less pronounced (Figure 4a ). We next subjected adriamycin and adriamycin plus TNF-atreated A549 cells to immunoprecipitations to evaluate the interactions between endogenous COX-2 and p53 under stress-induced conditions. Figure 4b shows that, indeed, endogenous p53 does co-precipitate with endogenous COX-2 using COX-2-specific antibodies. Additionally, exogenously expressed COX-2 and endogenous p53 also co-immunoprecipitated with one another in HCT-116 cells using anti-COX-2 antibodies (Figure 4c) . In a reciprocal experiment, p53 and COX-2 were exogenously expressed in PC-3 cells and immunoprecipitated with anti-p53 antibodies. As shown in Figure 4d , COX-2 immunoprecipitated with p53. It therefore appears that both molecules exhibit bona fide interactions and that their interactions are physiologically relevant.
The aberrant overexpression of COX-2 noted in various malignancies could continue to negatively affect p53 function in tumors that harbor wild-type p53, and thus COX-2 abrogation of p53 function has a clinical relevance. We therefore wished to evaluate the effect of the COX-2 selective inhibitor SC-236 on p53-mediated apoptosis. We reasoned that if COX-2 negatively interferes with p53 function then the COX-2 inhibitor should, in principle, relieve p53 from the negative influence of COX-2. To this end, we treated p53-inducible DLD1 human colon cancer cells with SC-236 under p53-induced and uninduced conditions and evaluated p53-mediated apoptosis. As shown in Figure 3 COX-2 overexpression does not alter p53 protein levels or subcellular localization. (a, b) Wild-type p53 expressing HCT-116 human colon cancer or MCF-7 human breast cancer cells were transiently transfected at approximately 60-70% efficiency in 60 mm plates with either empty pSG5 (Vector) or pSG5-COX-2 expression vector (COX-2) for 12-16 h using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). Cells were allowed to express for specified amounts of time before harvesting. Approximately 150 mg of total protein was subjected to SDS-PAGE and Western blotting using goat anti-COX-2 and mouse anti-p53 (DO-1, Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA) antibodies. (c) Cell pellets from untransfected (UT), pSG5 (Vector) or pSG5-COX-2 (COX-2) transfected HCT-116 cells were suspended in buffer A (10 mM HEPES (pH 7.4), 1 mM EDTA, 1 mM EGTA, 10 mM KCl, 1 mM DTT þ protease and phosphatase inhibitors) and subjected to Dounce homogenization. Cytosolic fractions (C) were then separated from intact nuclei by centrifugation. Intact nuclei were resuspended and lysed in buffer C (10 mM HEPES (pH 7.9), 25% glycerol, 0.1 mM EDTA, 0.1 mM EGTA, 350 mM NaCl þ inhibitors). Nuclear lysate was then subject to high-speed centrifugation and the resulting supernatant was collected as nuclear fraction (N). Western analysis was performed on 50 mg of each fraction using goat anti-COX-2, mouse anti-p53 (DO-1), mouse anti-LaminB (Oncogene Research, San Diego, CA, USA), and mouse anti-b-actin antibodies. Experiments were carried out multiple times and similar results were obtained Figure 5 , SC-236 clearly potentiates p53-mediated apoptosis, a finding which supports the notion that COX-2 activation does seem to interfere with p53 function.
In this study, we demonstrate that COX-2 is upregulated following p53 activation. We also demonstrate that COX-2 negatively affects the transcriptional function of p53 and that COX-2 may mediate such effects by physically interacting with p53. Additionally, a COX-2 selective inhibitor potentiates p53-induced apoptosis, which also supports the idea that COX-2 activity does appear to interfere with p53 function.
Our results indicate that p53-mediated COX-2 upregulation occurs at both the mRNA and protein levels, and whether COX-2 is a direct transcriptional target of p53 remains to be elucidated. We were unable to find a consensus p53-binding site within the COX-2 promoter region. Furthermore, since it has been well established that p53-binding sites are also present in the introns, as is the case for MDM2 and DR5, we have also evaluated the sequence of nine introns of the COX-2 gene and again a consensus p53-binding site was not found. Nonetheless, our results also indicate that COX-2 mRNA levels increase within 4 h and decline thereafter, whereas protein levels peak at 8 h and stay elevated until 24 h following p53 induction. These results would suggest that, in addition to transcriptional/post-transcriptional controls, COX-2 levels could also be controlled at the translational/post-translational levels following p53 induction. Future studies will enable us to elucidate among these alternatives.
COX-2 is a positive regulator of growth, whereas p53 is a negative regulator, and thus p53 upregulation of COX-2 would appear rather incongruous. However, based on our current results, we propose that p53 may abate its own growth arrest and/or apoptotic functions partially by upregulating COX-2. p53-mediated upregulation of positive growth regulators is not without precedence. For example, p53 upregulates MDM2 that in turn negatively affects p53 function by promoting p53 Figure 4 COX-2 interacts with p53. (a) Western blot analysis to show adriamycin and/or TNF-a regulation of COX-2 and p53 in A549 human lung cancer cells. Cells were treated with adriamycin (500 nM), TNF-a (10 ng/ml), or adriamycin plus TNF-a, and Western blotting was performed using standard procedures. (b) Endogenous COX-2 interacts with endogenous p53 in A549 cells. Cells were treated with adriamycin or adriamycin plus TNF-a for 8 h. Cells were harvested and 500 mg of protein samples were subject to immunoprecipitation with goat anti-COX-2 or with normal goat IgG (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA) as a negative control. The same blot was sequentially probed with COX-2 and p53-specific (DO-1) antibodies. To confirm comparable protein input, 20% supernatant of respective samples following immunoprecipitation was subjected to Western analysis and probed for b-actin as shown. (c) Exogenous COX-2 interacts with endogenous p53 in HCT-116 cells. Cells were treated with adriamycin (1 mM) for 8 h and 500 mg of protein was immunoprecipitated with anti-COX-2 antibodies. The same blot was sequentially probed for COX-2 and p53-specific (DO-1) antibodies. (d) Exogenous COX-2 interacts with p53. PC-3 cells were transiently transfected with p53 and COX-2 expression vectors for 14-16 h. Approximately 500 mg of total protein was subjected to immunoprecipitation using mouse anti-p53 antibodies (Ab-1) or with normal mouse IgG as a negative control. The same blot was sequentially probed with COX-2 and p53-specific (DO-1) antibodies. To confirm comparable protein input, 20% supernatant of the respective samples following immunoprecipitation were subjected to Western analysis and probed for b-actin as shown Figure 5 COX-2 inhibitor SC-236 potentiates p53-induced apoptosis. DLD1 cells carrying inducible p53 were grown in the presence or absence of 10 or 50 mM SC-236 under p53-repressed (Dox þ ) or p53-induced (Dox À) conditions. At 24 h, apoptotic cells were then detected by morphological analysis as we have described previously (Huang et al., 2001) . The results of two independent experiments are shown degradation. Additionally, the ubiquitin ligases Pirh2 and COP1 are direct p53 targets that also have been found to target p53 for proteasomal degradation (Leng et al., 2003; Corcoran et al., 2004; Dornan et al., 2004) . Our current results show that COX-2 clearly affects the transcriptional activation function of p53. However, since COX-2 overexpression does not appear to affect the endogenous p53 levels in wild-type p53 expressing MCF-7 and HCT-116 cell lines, COX-2 may not abrogate p53 function by decreasing p53 protein stability. Likewise, overexpression of COX-2 in HCT-116 cells does not appear to alter the subcellular distribution of p53 and therefore may not affect p53 by decreasing its nuclear localization. A recent report has shown that the treatment of HCT-116 cells with the COX-2 selective inhibitor celecoxib for 24 h induced p53 levels (Swamy et al., 2003) . It might therefore be expected then that overexpression of COX-2 in these cells would lead to decreased p53 levels. Since higher doses of nonsteroidal anti-inflammatory drugs, including celecoxib, have been shown to induce growth arrest and apoptosis in a COX-2-independent manner (Grosch et al., 2001; Shureiqi et al., 2001; Kulp et al., 2004) , it is possible that increases in p53 protein levels following celecoxib treatment as was reported could result from the COX-2-independent effects of celecoxib.
Although COX-2 and p53 exhibit mutual interactions, whether these interactions contribute to the abrogation of p53 transcriptional function or whether the metabolic products of COX-2 are responsible for inhibiting p53 is currently unclear. Nonetheless, we propose that p53-dependent upregulation and activation of COX-2 appear to be yet another novel mechanism via which p53 may abate, at least in part, its own growth-inhibitory and apoptotic effects. It is clear that both p53 and COX-2 are inducible proteins whose expression and activity are under tight regulatory controls. Aberrations in the activities of both have been associated with tumorigenesis. For example, p53 is frequently inactivated in various types of cancers, while COX-2 is overexpressed in a variety of malignancies. Our current findings highlight the existence of an interplay between these two very important molecules. It is likely that the mechanisms that affect this interplay are bound to have important consequences on normal cellular homeostasis. For example, it is well established that p53, dubbed 'the guardian of genome', is induced following DNA damage and plays a vital role in DNA damage repair (Lloyd and Hanawalt, 2002; Seo et al., 2002) . COX-2 expression is also induced following DNA damage (Han et al., 2002) . Since COX-2 negatively regulates p53, it is reasonable to suggest then that the aberrant constitutive overexpression of COX-2 noted in various malignancies could continue to negatively affect p53 function in tumors that harbor wild-type p53. With respect to the chemopreventive effects of COX-2 inhibitors, it is possible that such agents, by inhibiting COX-2, could protect wild-type p53 from the negative effects of COX-2, thereby enabling p53 to continue to guard against tumor development. Although strictly speculative at this stage, such a possibility might prove to be the basis of a novel mechanism by which the COX-2 inhibitors mediate, at least in part, their cancer-preventive effects. Thus, further studies will be essential to gain additional insights into the complex relationship that has emerged between the tumor suppressor p53 and COX-2. Such studies would likely enhance our understanding of the malignant development and progression, as well as afford us the opportunity to further the development of novel, more effective and less toxic chemopreventive strategies.
